Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hisun Cooperates With MNCs To Tap International Market

This article was originally published in PharmAsia News

Executive Summary

After getting Eli Lilly's technology transfer on processing capreomycin raw material, Zhejiang Hisun Pharmaceutical is building a production line capable of producing 3 million to 5 million doses of capreomycin annually. The company will complete its registration and Good Manufacturing Practices authentication in China this year. It is also preparing documentation for World Health Organization registration and approval, and may be WHO's only supplier of capreomycin in China. Its doses will be ready for the international market in two years. Hisun has a joint venture with Xinghai Pharmaceutical and Spain Farmaprojects S. A. that taps on the latter's overseas sales channels. Besides the capreomycin collaboration, Lilly may consider acquiring Hisun's products still in development as well as use the Chinese firm to manufacture its drugs. (Click here for more - Chinese Language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts